State of Alabama

12/08/2025 | Press release | Distributed by Public on 12/08/2025 16:18

Preferred Drug List (PDL) and Pharmacy Quarterly Update

PDF Version

TO: Pharmacies, Physicians, Physician Assistants, Nurse Practitioners, Oral Surgeons, Optometrists, Dentists, FQHCs, RHCs, Mental Health Service Providers and Nursing Homes

RE: Preferred Drug List (PDL) and Pharmacy Quarterly Update

Effective January 1, 2026, the Alabama Medicaid Agency (Medicaid) will:

  1. Require prior authorization (PA) for glycerol phenylbutyrate (generic Ravicti) . Brand Ravicti will not require a PA and will be billed with a Dispense as Written (DAW) Code of 9. DAW Code of 9 indicates the following: Substitution Allowed by Prescriber but Plan Requests Brand. This value is used when the prescriber has indicated, in a manner specified by prevailing law, that generic substitution is permitted, but the plan requests the brand product to be dispensed .
  1. Require prior authorization for clemastine syrup (generic Tavist), conjugated estrogens tablets (generic Premarin tablets), fluticasone/vilanterol (generic Breo Ellipta), and mirabegron (generic Myrbetriq). Brand Breo Ellipta, Myrbetriq, and Premarin tablets will be preferred and will be billed with a DAW Code of 9. DAW Code of 9 indicates the following: Substitution Allowed by Prescriber but Plan Requests Brand. This value is used when the prescriber has indicated, in a manner specified by prevailing law, that generic substitution is permitted, but the plan requests the brand product to be dispensed .
  1. Update the PDL to reflect the quarterly updates listed below:

PDL Additions

alogliptin (generic Nesina)

Dipeptidyl Peptidase-4 Inhibitors (DPP-4)

Ebglyss CC

Skin & Mucous Membrane Immunomodulatory Agents

fluticasone/salmeterol (generic AirDuo Respiclick)

Respiratory Corticosteroids

Mounjaro CC

Incretin Mimetics

Myrbetriq

Genitourinary Smooth Muscle Relaxants: Beta-3 Adrenergic Agonists

Nemluvio CC

Skin & Mucous Membrane Immunomodulatory Agents

Premarin Cream

Estrogens

Rinvoq CC

TIMs/ DMARDs Agents

PDL Deletions

Brilinta

Platelet-aggregation Inhibitors/ Vasodilating Agents, Misc

Bydureon Bcise

Incretin Mimetics

clemastine syrup (generic Tavist)

First-Generation Antihistamine Agents

conjugated estrogens tabs (generic Premarin tabs)

Estrogens

fluticasone/vilanterol (generic Breo Ellipta)

Respiratory Corticosteroids

mirabegron (generic Myrbetriq)

Genitourinary Smooth Muscle Relaxants: Beta-3Adrenergic Agonists

Nesina

Dipeptidyl Peptidase-4 Inhibitors (DPP-4)

Toviaz

Genitourinary Smooth Muscle Relaxants: Antimuscarinics

CC This agent will be preferred with clinical criteria in place.

For additional PDL and coverage information, visit our drug look-up site at

https://www.medicaid.alabamaservices.org/alportal/NDC%20Look%20Up/tabId/5/Default.aspx.

The Prior Authorization Request Form(Form 369) and criteria booklet (Form 369/389 Instructions) should be utilized by the prescriber or the dispensing pharmacy when requesting a PA. The request form can be completed and submitted electronically at https://medicaid.alabama.gov/content/9.0_Resources/9.4_Forms_Library/9.4.13_Pharmacy_Forms.aspx.

Providers requesting PAs by mail or fax should send requests to:

Acentra Health

Medicaid Pharmacy Administrative Services

P.O. Box 3570, Auburn, AL 36831

Fax: 1-800-748-0116

Phone: 1-800-748-0130

Incomplete PA requests or those failing to meet Medicaid criteria will be denied. If the prescriber believes medical justification should be considered, the prescriber must document this on the form or submit a written letter of medical justification along with the PA form to Acentra Health. Additional information may be requested. Staff physicians will review this information.

State of Alabama published this content on December 08, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on December 08, 2025 at 22:18 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]